These include midostaurin for FLT3 mutant AML, venetoclax for raised BCL2 AML, ivosidenib/enasidenib for IDH mutant AML or gemtuzumab ozogamicin for CD33+ AML [3,4]. This evidence concerns the gene FLT3 and acute myeloid leukemia.